Hillsdale Investment Management Inc. Protalix Bio Therapeutics, Inc. Transaction History
Hillsdale Investment Management Inc.
- $1.77 Billion
- Q1 2025
A detailed history of Hillsdale Investment Management Inc. transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Hillsdale Investment Management Inc. holds 116,100 shares of PLX stock, worth $197,370. This represents 0.02% of its overall portfolio holdings.
Number of Shares
116,100Holding current value
$197,370% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding PLX
# of Institutions
69Shares Held
8.26MCall Options Held
227KPut Options Held
54.5K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.19MShares$2.02 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny963KShares$1.64 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA859KShares$1.46 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL685KShares$1.16 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0615KShares$1.05 Million0.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $84.6M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...